血液系统恶性肿瘤患者化疗后合并中性粒细胞减少性肠炎的诊治研究

目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎（NE）的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者，记录患者血常规、凝血检测和血液生化检测结果，并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等，探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例（12.5%）化疗后合并NE，化疗后10~19d起病，中位起病时间为化疗后第14天。发生NE后26例患者死亡，病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症，发生NE后患者病死率较高。     

Lower body mass index and higher height are correlated with increased varicocele risk

To evaluate the anthropometric indexes in subjects with varicocele compared to controls and the incidence of varicocele in different body mass index (BMI) groups for the purpose of exploring the association between varicocele and anthropometric indexes. A comprehensive literature search was conducted by using PubMed, MEDLINE, EMBASE databases and Cochrane Library up to February 2019. A systematic review and meta‐analysis was conducted by STATA, and Newcastle–Ottawa Scale was utilised for assessing risk of bias. Ultimately, 13 articles containing seven case–control studies and six cross‐sectional studies with 1,385,630 subjects were involved in our study. Pooled results demonstrated that varicocele patients had a lower BMI (WMD = ?0.77, 95% CI = ?1.03 to ?0.51) and a higher height than nonvaricocele participants, especially in grade 3 varicocele patients. Subgroup analyses showed that normal BMI individuals had a higher risk of varicocele than obese or overweight individuals and a lower risk than underweight individuals. In conclusion, this study indicates that varicocele patients have a lower BMI and a higher height than nonvaricocele participants. Moreover, men with excess bodyweight have a lower incidence of varicocele compared to normal weight or underweight people. That is to say, high BMI and adiposity protect against varicocele and high BMI is associated with a decreased risk of varicocele.     

miR-26b通过调节Notch1信号通路参与原发性肝细胞肝癌侵袭的机制研究

目的:探讨miR-26b参与原发性肝细胞肝癌（HCC）侵袭的机制。方法:在细胞培养液中培养人肝细胞系HL-7702和HCC细胞各系Hepb-3、HuH-7、MHCC97-L、MHCC97-H。实时荧光定量PCR法（qRT-PCR）检测miR-26b的表达水平；用miR-26b mimics、miR-26b inhibitors和Notch1-siRNA分别转染HCC细胞；MTT实验检测转染后HCC细胞的活力；采用Western blot检测Notch1受体蛋白表达水平的变化；Transwell小室测定不同处理后的HCC细胞的侵袭能力。结果:人正常肝细胞系HL-7702和HCC细胞系Hepb-3、HuH-7、MHCC97-L、MHCC97-H中的miR-26b相对表达含量随其侵袭和迁移能力的升高而依次下降；抑制miR-26b的表达，Notch1受体蛋白表达明显增高，而此时HCC细胞的侵袭性显著增强；相反，上调miR-26b的表达，Notch1受体蛋白表达明显降低，而HCC细胞侵袭性显著下降；miR-26b可能通过调控Notch1信号通路调节HCC细胞侵袭性。结论:miR-26b通过负调控Notch1信号通路抑制HCC细胞侵袭能力，为HCC侵袭的机制奠定了理论基础，miR-26b可能成为HCC治疗的新靶点。     

影像学在盆底器官脱垂的应用

随着整体理论、吊床理论及肛提肌维持盆底器官的重要性等多种观点的提出,盆底器官脱垂(POP)发病机制复杂临床表现多样化,因此获得POP的完整信息,应结合临床检查及辅助检查手段,在辅助检查手段中应用最广泛、最有优势的影像学技术。多种影像学技术应用于盆底,包括静态及动态盆底影像学技术,帮助临床医师全面了解POP的发病机制、诊断并建立盆底治疗方案及完善的术后随访体系。     

谷氨酰胺联合规范化早期肠内营养治疗对急性重症胰腺炎患者的疗效分析

目的探讨谷氨酰胺联合规范化早期肠内营养治疗对急性重症胰腺炎(SAP)患者的临床疗效。方法将我院2014年1月至2015年12月收治的96例SAP患者随机分为观察组与对照组,每组各48例。对照组患者采用全肠外营养(TPN)支持治疗,观察组采用谷氨酰胺联合规范化早期肠内营养治疗。分析比较两组的临床疗效。结果治疗第9 d后两组APACHEⅡ评分、TBIL、ALT、AST、BUN、Scr以及Hs-CRP、TNF-α、IL-1β、IL-6、IL-8水平均显著降低,IL-10水平显著升高,且观察组以上指标改善水平显著优于对照组,P<0.001。观察组患者住院时间、死亡率及感染率均显著低于对照组,P<0.05。结论谷氨酰胺联合规范化早期肠内营养治疗有助于改善SAP患者的氨基酸代谢情况,缓解负氮平衡,改善全身炎症状况,缩短住院时间,降低感染率及死亡率。     

Research progress on the biomimetic remineralization of hard tooth tissues based on polyamide-amine dendrimer

聚酰胺—胺树枝状聚合物（PAMAM）作为一种新型超支化大分子聚合物,因其出色的化学和生物学特性,一直被众学者称之为“人工蛋白”。 PAMAM的特点是存在内部空腔,并含有大量的反应性末端基团,这些结构使得PAMAM可以被用作仿生大分子,模拟天然有机基质在牙体组织表面进行仿生矿化,即PAMAM作为有机模板调控矿物质成核以及晶体的生长,以此来建造比传统的异体材料更加理想的牙体修复材料。本文就 PAMAM 诱导牙体硬组织仿生矿化的研究进展作一综述。     

广泛性焦虑障碍心理治疗研究进展

总结广泛性焦虑症(generalized anxiety disorder,GAD)心理治疗方法,分析不同心理治疗的疗效及研究进展,为今后多角度、整合式运用各种心理疗法治疗GAD提供新思路.     

Review of clinical characteristics,immune responses and regulatory mechanisms of hepatitis E-associated liver failure

Hepatitis E virus (HEV) is the most common cause of acute liver failure (LF) and one of the most common factors causing acute injury in acute-on-chronic LF (ACLF). When HEV-related LF occurs, a series of changes take place in both the intrahepatic environment and extrahepatic microenvironment. The changed types and distribution of immune cells (infiltrating macrophages and increased lymphocytes) in liver tissue, as well the increased proinflammatory cytokines and chemokines in the blood, indicate that the occurrence and progression of HEV-related LF are closely related to immune imbalance. The clinical features and immune reaction in the body during HEV-related acute LF (ALF) and ACLF are complicated. This review highlights recent progress in elucidating the clinical manifestations of HEV-associated ALF and ACLF and discusses the corresponding systemic immune changes and possible regulatory mechanisms.